Zhengye Biotechnology-AZYBT
13F holders, Q2 2025 (June 30)9holders +6
6new positions
0sold out
$5.97avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Zhengye Biotechnology-A (ZYBT) in their 13F filings, up 6 from Q1 2025. 6 opened new positions and 0 sold out. The largest holders were Jane Street Group, LLC ($1.2M), UBS Group AG ($922K) and Invesco Ltd. ($220K).
- Company
- Zhengye Biotechnology-A
- CUSIP
- G989MS101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $1.6M |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 419,206 shares bought, net +419,206 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Jane Street Group, LLC | 0.00% | New | 193,982 | $1.2M |
| UBS Group AG | 0.00% | Add +11887.0% | 154,512 | $922K |
| Invesco Ltd. | 0.00% | New | 36,839 | $220K |
| Geode Capital Management, LLC | 0.00% | New | 29,068 | $174K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +333500.0% | 3,336 | $20K |
| Morgan Stanley | 0.00% | Add +5195.6% | 2,436 | $15K |
| BNP Paribas Financial Markets | 0.00% | New | 262 | $2K |
| Bank of America Corp. | 0.00% | New | 73 | $436 |
| Royal Bank of Canada | 0.00% | New | 34 | $0 |
"% of holder's portfolio" is ZYBT's weight in each manager's 13F, not the share of Zhengye Biotechnology-A the manager owns.